tag:blogger.com,1999:blog-7857054149675424609.post7394890802796145870..comments2024-02-24T08:58:08.581+00:00Comments on RNAi Therapeutics: Silence Therapeutics Signs Lung Delivery Deal with Mystery PartnerDirk Hausseckerhttp://www.blogger.com/profile/18320439857875629714noreply@blogger.comBlogger2125tag:blogger.com,1999:blog-7857054149675424609.post-81042239451083688532011-09-28T01:15:14.147+00:002011-09-28T01:15:14.147+00:00Lung fibrosis, of course, is a big issue and large...Lung fibrosis, of course, is a big issue and largely untapped market. However, with miR-21 and fibrosis you would probably want to inhibit it in fibroblasts, not endothelial cells where the DACC system seems to go. There are miRNA-inhibitors that would benefit from a delivery system like DACC. However, most microRNA inhibitions still attempt the 'naked' administration of phosphorothioateDirk Hausseckerhttps://www.blogger.com/profile/18320439857875629714noreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-19603319798936626512011-09-27T23:06:23.386+00:002011-09-27T23:06:23.386+00:00Who owns MiR-21? That would appear a valid pulmona...Who owns MiR-21? That would appear a valid pulmonary fibrosis microrna target.Anonymousnoreply@blogger.com